7ENQ image
Deposition Date 2021-04-19
Release Date 2022-05-04
Last Version Date 2023-11-29
Entry Detail
PDB ID:
7ENQ
Keywords:
Title:
Crystal structure of human NAMPT in complex with compound NAT
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.23
R-Value Work:
0.17
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Nicotinamide phosphoribosyltransferase
Gene (Uniprot):NAMPT
Chain IDs:A, B, C, D
Chain Length:497
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity.
Cell Res. 32 570 584 (2022)
PMID: 35459935 DOI: 10.1038/s41422-022-00651-9

Abstact

The decline of nicotinamide adenine dinucleotide (NAD) occurs in a variety of human pathologies including neurodegeneration. NAD-boosting agents can provide neuroprotective benefits. Here, we report the discovery and development of a class of potent activators (NATs) of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD salvage pathway. We obtained the crystal structure of NAMPT in complex with the NAT, which defined the allosteric action of NAT near the enzyme active site. The optimization of NAT further revealed the critical role of K189 residue in boosting NAMPT activity. NATs effectively increased intracellular levels of NAD and induced subsequent metabolic and transcriptional reprogramming. Importantly, NATs exhibited strong neuroprotective efficacy in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) without any overt toxicity. These findings demonstrate the potential of NATs in the treatment of neurodegenerative diseases or conditions associated with NAD level decline.

Legend

Protein

Chemical

Disease

Primary Citation of related structures